文献速递肝病消化道肿瘤与早癌

RORα对肝脏驻留NK细胞/ILC1维持及抗肿瘤免疫的必要性

Requirement of RORα for maintenance and antitumor immunity of liver-resident natural killer cells/ILC1s.
PubMed 文献 · Hepatology · 2021-12-06

本研究探讨RORα在肝脏驻留自然杀伤(LrNK)细胞/1型先天淋巴样细胞(ILC1)维持和功能中的作用。条件性敲除Rorα的小鼠中LrNK细胞/ILC1数量减少、凋亡增加且转录谱改变,而常规NK细胞数量正常;在结直肠癌肝转移模型中,RORα缺失导致肝肿瘤进展更侵袭、效应分子表达受损,而RORα激动剂治疗可限制肝转移并促进效应分子表达。

要点

  • RORα在LrNK细胞/ILC1中高表达,对其维持至关重要。
  • RORα缺陷导致LrNK细胞/ILC1凋亡增加、数量减少,但不影响cNK细胞。
  • RORα激动剂可限制肝转移并增强LrNK细胞/ILC1效应功能。

核心结论

  • RORα是维持LrNK细胞/ILC1数量和抗肿瘤功能的关键因子,激动RORα可限制肝转移。

研究设计与样本

  • 研究使用条件性敲除Rorα(在LrNK细胞/ILC1和cNK细胞中)的小鼠模型,并采用结直肠癌肝转移模型。

主要发现

  • RORα条件性缺失导致LrNK细胞/ILC1数量减少、凋亡增加、转录谱显著改变,而cNK细胞数量正常。
  • 在结直肠癌肝转移模型中,RORα缺失导致肝肿瘤进展更侵袭、LrNK细胞/ILC1效应分子表达受损。
  • RORα激动剂治疗有效限制肝转移并促进LrNK细胞/ILC1效应分子表达。

临床怎么用

  • RORα激动剂可能成为通过增强LrNK细胞/ILC1活性治疗肝癌的潜在策略。

局限性

  • 研究基于小鼠模型,结果尚未在人体中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUD AND AIMS: Liver type 1 innate lymphoid cells (ILC1s), also known as liver-resident natural killer (LrNK) cells, comprise a high proportion of total hepatic ILCs. However, factors regulating their maintenance and function remain unclear. APPROACH AND RESULTS: In this study, we found high expression of retinoid-related orphan nuclear receptor alpha (RORα) in LrNK cells/ILC1s. Mice with conditional ablation of retinoid-related orphan nuclear receptor alpha (Rorα) in LrNK cells/ILC1s and conventional natural killer (cNK) cells had decreased LrNK cells/ILC1s but normal numbers of cNK cells. RORα-deficient LrNK cells/ILC1s displayed increased apoptosis and significantly altered transcriptional profile. Using a murine model of colorectal cancer liver metastasis, we found that RORα conditional deficiency resulted in more aggressive liver tumor progression and impaired effector molecule expression in LrNK cells/ILC1s. Consequently, treatment with the RORα agonist efficiently limited liver metastases and promoted effector molecule expression of LrNK cells/ILC1s. CONCLUSIONS: This study reveals a role of RORα in LrNK cell/ILC1 maintenance and function, providing insights into the harnessing of LrNK cell/ILC1 activity in the treatment of liver cancer.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Song J, Song H, Wei H, et al. Requirement of RORα for maintenance and antitumor immunity of liver-resident natural killer cells/ILC1s. Hepatology. 2021. PMID: 34510508. doi:10.1002/hep.32147

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。